New Turkish Biosimilar Insulin Glargine Poses Challenge For Sanofi’s Lantus

 
• By Ahmet Sevindik
  
Diabetes-Concept_56048224_1200x675
Biosimilar insulin glargine could lead to changes in Turkish diabetes market
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Manufacturing

More from Business